by myNEO Tx Admin | May 30, 2024 | Article, News
mRNA construct design can be challenging. Read this case study to learn more about how to design multi-epitope mRNA constructs to optimize translation efficiency and target-specific immunogenicity while avoiding junctional epitopes. Read case studyby myNEO Tx Admin | Apr 30, 2024 | Team events
Over the past few months, we organized our second table football spring cup, bringing together our team for some friendly competition β½οΈIn an intense battle for first place, Bruno Fant emerged victorious against Lore Van Oudenhove. In the small final, Lena Pfitzer...by myNEO Tx Admin | Mar 8, 2024 | News
Today, on #internationalwomensday , we’re proud to celebrate the remarkable women of myNEO Therapeutics. Their talent, dedication, and leadership are at the heart of our success. Thank you for your invaluable contributions! #womeninhealthcareby myNEO Tx Admin | Feb 17, 2024 | Team events
Every week we gather for office workouts πββοΈ led by Lien Lybaert. It’s a great way to stay fit and foster a healthy work environment at myNEO Therapeutics. #WorkoutWednesdayby myNEO Tx Admin | Feb 15, 2024 | News
Last week, our team came together for an engaging and informative training session about the cloud-based version of our ImmunoEngine led by Lore Van Oudenhove and Steve Lefever. These training sessions demonstrate our dedication to continuous improvement and knowledge...The process starts with the collection of both patient blood and a tumor biopsy.
Whole-Genome Sequencing data from matched tumor and normal DNA is required for each patient.
Following alignment of these reads to the genome, somatic gene alterations in the tumor genome are detected using a collection of algorithms called 'neoX'.
Next, these somatic gene alterations are translated in-silico to obtain the tumor-specific peptides
In a last step, the peptides are prioritized using an immunogenicity predictor (neoIM) and two presentation predictors (neoMS and MHCrank).